Jeremy M. Levin - 08 Apr 2022 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
CEO, Director, 10%+ Owner
Signature
/s/ Danielle Mann for Jeremy Levin by PoA
Issuer symbol
OVID
Transactions as of
08 Apr 2022
Transactions value $
$0
Form type
4
Filing time
12 Apr 2022, 17:36:41 UTC
Previous filing
04 Feb 2022
Next filing
27 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +423K $0.00 423K 08 Apr 2022 Common Stock 423K $3.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.